Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Apr 14, 2026
Reporting period
Not applicable
Filed with the SEC
Apr 16, 2026
DirectorIndirect holdingOther
Context
Classification
other
Code P in the derivative table; not an open-market share purchase
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0000947871-26-000449
Filed / recorded
Apr 16, 2026, 11:31 PM UTC
Added to OQRO
Oct 8, 2026, 2:41 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
ImageneBio, Inc.
Issuer CIK
1835579
Ticker
IMA
Reporting person
David P Bonita
Relationship
Director
Security
Pre-Funded Warrants (right to buy)
Table
Derivative (Table II)
Transaction date
Apr 14, 2026
Transaction code
P
Shares / units
336,603
Acquired / disposed
Acquired (A)
Shares owned after
336,603
Ownership form
Indirect — See Footnote
Amendment
No
Footnotes from the filing
On April 12, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain institutional and accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to OrbiMed Private Investments VI, LP ("OPI VI") and OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund") in a private placement which closed on April 14, 2026 (the "Closing Date") pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 721,292 Shares. The price per Pre-Funded Warrant is $5.199.
The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 19.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full.
These securities are held of record by OPI VI. OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.
Each of the Reporting Person, OrbiMed Advisors, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
2 tracked managers disclosed the same change for Q1 2026. From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
